Oramed Pharmaceuticals (ORMP) Q3 2025 earnings summary

Executive summary

• Achieved net income of $54.0M for the nine months ended September 30, 2025, compared to a net loss of $8.9M in the prior year period, driven by significant financial income from investments and asset revaluations.

• Recognized $2.0M in revenue from the HTIT License Agreement following mutual waivers and termination of the JV Agreement.

• Major investment and strategic partnership activity included the Alpha Tau acquisition, Scilex transactions, and real estate investments.

• Management highlights increased financial flexibility to pursue strategic opportunities and advance the oral drug delivery platform.

Financial highlights

• Revenues were $2.0M for the nine months ended September 30, 2025, with cost of revenue at $2.0M, resulting in a gross profit of $13K.

• Net income attributable to stockholders was $54.0M for the nine months, compared to a net loss of $8.9M in the prior year.

• Financial income, net, was $74.3M for the nine months, primarily from revaluation of Alpha Tau and Scilex investments.

• Research and development expenses decreased 10% year-over-year to $4.4M; general and administrative expenses increased 16% to $5.0M.

• Cash and cash equivalents at period end were $52.2M, with total assets of $220.5M and stockholders’ equity of $203.3M.

Outlook and guidance

• Plans to initiate a 60-patient US-based clinical trial targeting high-responder subgroups for oral insulin, aiming for rapid and cost-effective validation.

• Anticipates increased R&D expenses as new clinical trials commence, but current cash resources are expected to support planned activities for at least 12 months.

• Management anticipates continued growth through disciplined investment strategy and expects to leverage financial flexibility for strategic initiatives.